What is the clinical evidence from this study?

Study design: Other. Population: Cardiac fibrosis. Intervention: Adenosine A2B receptor agonist (CV1808) vs. Vehicle / ET-1 alone. Primary outcome: ET-1-induced fibroblast proliferation and α-SMA expression (p=<0.05).

June 30, 2017Frontiers in PharmacologyOpen Access

Stimulation of Adenosine A2B Receptor Inhibits Endothelin-1-Induced Cardiac Fibroblast Proliferation and α-Smooth Muscle Actin Synthesis Through the cAMP/Epac/PI3K/Akt-Signaling Pathway

Q: What are the key findings of this study?

Stimulation of the adenosine A2B receptor significantly inhibited endothelin-1-induced cardiac fibroblast proliferation and α-smooth muscle actin expression via the cAMP/Epac/PI3K/Akt signaling pathway.

View Full Paper

Ask AI

Bookmark

Key result

Stimulation of the adenosine A2B receptor significantly inhibited endothelin-1-induced cardiac fibroblast proliferation and α-smooth muscle actin expression via the cAMP/Epac/PI3K/Akt signaling pathway.

Why the study?

Does adenosine A2 receptor agonist CV1808 prevent ET-1-induced cell proliferation and α-SMA expression in neonatal rat cardiac fibroblasts?

Population

Neonatal Sprague-Dawley rat cardiac fibroblasts

Comparison

Adenosine A2 receptor agonist CV1808 for 1 hour… vs Vehicle prior to Endothelin-1 stimulation

Design

Preclinical

Authors

SPSarawuth PhosriMahidol University AAAjaree ArieyawongMahidol University KBKwanchai BunrukchaiMahidol University

Discussion

Member takes

Implication

May not yet guide antifibrotic therapy; leaves open A2B receptor as a target for cardiac fibrosis research.

Structured PICO

Does adenosine A2 receptor agonist CV1808 prevent ET-1-induced cell proliferation and α-SMA expression in neonatal rat cardiac fibroblasts?

Population

In vitro study using neonatal rat cardiac fibroblasts to evaluate the mechanisms of cardioprotective effects of adenosine receptor agonists.

Intervention

Adenosine A2 receptor agonist CV1808 (1-50 µM) for 1 hour prior to Endothelin-1 (20 nM) stimulation for 12-24 hours

Comparator

Vehicle (control) prior to Endothelin-1 (20 nM) stimulation

Outcome

Cell proliferation (assessed by MTT assay) and α-SMA mRNA and protein expressionsurrogate

Main Result

p-value: p=<0.05

Stimulation of the adenosine A2B receptor inhibits ET-1-induced cardiac fibroblast proliferation and α-SMA synthesis via the cAMP/Epac/PI3K/Akt pathway, identifying a potential therapeutic target for cardiac fibrosis.

Limitations

In vitro experiment using cardiac fibroblasts may not completely apply for clinical use due to lacking in vivo and clinical studies
MTT assay may not completely apply for investigation of antiproliferative effect
Restorative roles of A2B receptor following ET-1 administration have not been determined

Cite This Study

Phosri et al. (2017) studied Cardiac fibrosis. Adenosine A2B receptor agonist (CV1808) vs. Vehicle / ET-1 alone was evaluated on ET-1-induced fibroblast proliferation and α-SMA expression (p=<0.05). Stimulation of the adenosine A2B receptor significantly inhibited endothelin-1-induced cardiac fibroblast proliferation and α-smooth muscle actin expression via the cAMP/Epac/PI3K/Akt signaling pathway.

synapsesocial.com/papers/6a21bd408d200acffec0ad7c https://doi.org/10.3389/fphar.2017.00428

View Full Paper

Ask AI

Bookmark

June 30, 2017Frontiers in PharmacologyOpen Access

Stimulation of Adenosine A2B Receptor Inhibits Endothelin-1-Induced Cardiac Fibroblast Proliferation and α-Smooth Muscle Actin Synthesis Through the cAMP/Epac/PI3K/Akt-Signaling Pathway

View Full Paper

Ask AI

Bookmark

Key result

Why the study?

Does adenosine A2 receptor agonist CV1808 prevent ET-1-induced cell proliferation and α-SMA expression in neonatal rat cardiac fibroblasts?

Population

Neonatal Sprague-Dawley rat cardiac fibroblasts

Comparison

Adenosine A2 receptor agonist CV1808 for 1 hour… vs Vehicle prior to Endothelin-1 stimulation

Design

Preclinical

Authors

SPSarawuth PhosriMahidol University AAAjaree ArieyawongMahidol University KBKwanchai BunrukchaiMahidol University

Discussion

Member takes

Implication

May not yet guide antifibrotic therapy; leaves open A2B receptor as a target for cardiac fibrosis research.

Structured PICO

Does adenosine A2 receptor agonist CV1808 prevent ET-1-induced cell proliferation and α-SMA expression in neonatal rat cardiac fibroblasts?

Population

In vitro study using neonatal rat cardiac fibroblasts to evaluate the mechanisms of cardioprotective effects of adenosine receptor agonists.

Intervention

Adenosine A2 receptor agonist CV1808 (1-50 µM) for 1 hour prior to Endothelin-1 (20 nM) stimulation for 12-24 hours

Comparator

Vehicle (control) prior to Endothelin-1 (20 nM) stimulation

Outcome

Cell proliferation (assessed by MTT assay) and α-SMA mRNA and protein expressionsurrogate

Main Result

p-value: p=<0.05

Limitations

In vitro experiment using cardiac fibroblasts may not completely apply for clinical use due to lacking in vivo and clinical studies
MTT assay may not completely apply for investigation of antiproliferative effect
Restorative roles of A2B receptor following ET-1 administration have not been determined

Cite This Study

synapsesocial.com/papers/6a21bd408d200acffec0ad7c https://doi.org/10.3389/fphar.2017.00428

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark